FILING ANALYSIS · THURSDAY, NOVEMBER 5
Cogent Biosciences, Inc. COGT — 8-K: Results of Operations and Financial Condition
neutral
Cogent Biosciences reported a cash balance of $791.1 million, which is expected to fund operations into late 2028, and announced several upcoming milestones, including potential FDA approvals for bezuclastinib in GIST, NonAdvSM, and AdvSM, but no quantified surprises were disclosed in the filing.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →